Literature DB >> 11261736

Tolerability of doxofylline in the maintenance therapy of pediatric patients with bronchial asthma.

G F Bagnato1.   

Abstract

A retrospective open study was performed to ascertain the tolerability of doxofylline in pediatric patients with bronchial asthma or airway obstruction complicating acute bronchitis. The study population included 806 patients aged between 3 and 16 years. Doxofylline (200 mg sachets) was administered at daily doses ranging from 100 to 400 mg. The percentage of patients reporting side effects was 11%. The percent of patients reporting moderate side effect was 5%, the others being mild. The percent of patients reporting adverse event very likely due to doxofylline was 6%. The percent of patient drop-outs related to side effects was 5%.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11261736

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  To study the efficacy and safety of doxophylline and theophylline in bronchial asthma.

Authors:  Sami Manzoor Margay; Samina Farhat; Sharanjit Kaur; Hilal Ahmad Teli
Journal:  J Clin Diagn Res       Date:  2015-04-01

Review 2.  Doxofylline for Pediatric Asthma Steps 1-4. Pediatric Asthma: New Role for an Old Drug.

Authors:  Vincenzo Fierro; Anna Lucia Piscitelli; Edda Battaglia; Alessandro Fiocchi
Journal:  Front Pediatr       Date:  2022-06-22       Impact factor: 3.569

3.  Spectrophotometric and reversed-phase high-performance liquid chromatographic method for the determination of doxophylline in pharmaceutical formulations.

Authors:  Hr Joshi; Ah Patel; Ad Captain
Journal:  J Young Pharm       Date:  2010-07

Review 4.  Doxofylline: The next generation methylxanthine.

Authors:  Jhuma Sankar; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2008-03       Impact factor: 1.967

5.  Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Authors:  Paola Rogliani; Luigino Calzetta; Josuel Ora; Mario Cazzola; Maria Gabriella Matera
Journal:  Multidiscip Respir Med       Date:  2019-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.